Chargement en cours...
Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life
OBJECTIVE: The aim of this study was to determine if direct-acting antiviral (DAA) treatment with daclatasvir (DCV) plus asunaprevir (ASV) for 24 weeks influenced the health-related quality of life (HRQOL) at 12 and 24 weeks after treatment initiation [end of treatment (EOT)]. METHODS: This was a pr...
Enregistré dans:
| Publié dans: | Intern Med |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
The Japanese Society of Internal Medicine
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6096027/ https://ncbi.nlm.nih.gov/pubmed/29526929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0091-17 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|